240 results about "Ceramide AP" patented technology

Glycosylceramide analogues are disclosed in which the ceramide moiety and optionally the carbohydrate moiety are modified or replaced. These analogues are useful as immunomodulators, antitumor agents, and as other pharmaceutical agents.

An encapsulated delivery system, and, in particular, a nanoparticulate delivery system representing a qualitatively different approach to overcoming multi-drug resistance while simultaneously administering the chosen drug treatment to a patient, e.g., in a site-specific manner, is disclosed. A composition according to the invention includes a therapeutically effective amount of one or more multi-drug resistance reversing agents selected from the group consisting of ceramide and ceramide modulators; and a therapeutically effective amount of a therapeutic agent, wherein the therapeutic agent is different from the one or more multi-drug resistance reversing agents, and the one or more multi-drug resistance reversing agents and the therapeutic agent are encapsulated, preferably co-encapsulated, in a biocompatible, biodegradable delivery vehicle for delivery to a patient in need of treatment, for example, for specific localization at, or higher probability of delivery to, a treatment site in a patient administered the composition. Preferably, the one or more multi-drug resistance reversing agents are ceramide, paclitaxel or tamoxifen.

The invention discloses a ceramide nano-emulsion and a preparation method thereof. The ceramide nano-emulsion is composed of the following components by weight percentage: 0.1-8% of ceramide, 0.01-5% of emulgator, 5-30% of grease, 6-20% of polyhydric alcohols, 0.01-1% of inorganic salt and the balance of water. The preparation method comprises the following steps: mixing the ceramide and the grease and heating till the ceramide is completely dissolved; adding the emulgator and the polyhydric alcohols to obtain an oil phase component, mixing the inorganic salt with the water to obtain a water phase component, respectively heating the oil phase component and the water phase component to 80-90 DEG C, adding the water phase component into the oil phase component, homogenizing and emulsifying; performing high-pressure homogenizing on the obtained crude emulsion under the pressure of 150-600 bar under the condition that the number of cycle is 2-5 to obtain the ceramide nano-emulsion, wherein after the ceramide nano-emulsion is stored for 30d at a high temperature of 50 DEG C, the particle size is basically the same. The ceramide nano-emulsion is excellent in water dispersibility and biocompatibility and can be randomly matched with the cosmetic formula at normal temperature.

Provided is a ceramide emulsion containing the following components (A), (B) and (C) and not containing an acrylic acid polymer or a phospholipid: (A) sphingosines represented by Formula (1): (wherein R1 represents a hydrocarbon group having 4 to 30 carbon atoms which is optionally substituted with a hydroxyl group and the like; Y represents CH2, CH or O; X1, X2 and X3 represent H, a hydroxyl group or an acetoxy group; X4 represents H, an acetyl group or a glyceryl group or, together with an adjacent O atom, forms an oxo group; R2 and R3 represent H, a hydroxyl group, a hydroxymethyl group or an acetoxymethyl group; groups “R”s are H or an amidino group or represent a hydrocarbon group having 1 to 8 carbon atoms which may have a substituent such as a hydroxyl group and the like; and “a” is 2 or 3), (B) an acidic compound selected from inorganic acids and organic acids having a molecular weight of 200 or less, and (C) ceramides represented by Formula (2): (wherein R7 represents a hydrocarbon group having 4 to 30 carbon atoms which is optionally substituted with a hydroxyl group and the like; Z represents CH2, CH or O; X5, X6 and X7 represent H, a hydroxyl group or an acetoxy group, X4 represents H, an acetyl group or a glyceryl group or, together with an adjacent O atom, forms an oxo group; R8 and R9 represent H, a hydroxyl group, a hydroxymethyl group or an acetoxymethyl group; R10 represents a hydrocarbon group having 5 to 60 carbon atoms which is optionally substituted with a hydroxyl group and the like; and R11 represents H or a hydrocarbon group having 1 to 8 carbon atoms which optionally have a substituent such as a hydroxyl group and the like).

The invention belongs to the technical field of biomedical, and specifically relates to a composition for promoting skin barrier repair and an application thereof. The composition for promoting skin barrier repair includes the following components in parts by weight: 10-20 wt% of trehalose, 10-30 wt% of sodium hyaluronate, 5-15 wt% of a herba centellae extract, 5-15 wt% of spirulina polysaccharide, 5-15 wt% of collagen, 5-20 wt% of an aloe extract, 1-5 wt% of ceramide, 1-5 wt% of poly(sodium L-glutamate), 1-2 wt% of ascorbyl glucoside, and 0.5-2 wt% of acetylchitosamine. The prepared composition can be used for promoting the repair after skin barriers are damaged, is especially suitable for repair of skin barrier damage after laser cosmetic treatment.

The invention discloses a metabolic marker combination for evaluating the risks of cardiovascular and cerebrovascular disease of a subject. The metabolic marker combination comprises ceramide Cer d18:1 / 16:0, ceramide Cer d18:1 / 18:0, ceramide Cer d18:1 / 24:0, phenylacetyl glutamine, trimethylamine, glycine betaine and choline. The cardiovascular and cerebrovascular diseases are selected from coronary heart disease, atherosclerosis, atrial fibrillation and heart failure. The metabolic marker combination disclosed by the invention has the advantages of high sensitivity, good specificity, quantification, high detection flux and the like in the aspect of evaluating or predicting the risks of cardiovascular and cerebrovascular diseases.

The present invention concerns a new medical treatment involving the combination of two active entities, as well as pharmaceutical compositions comprising the two active entities. Specifically, the invention provides a pharmaceutical composition comprising a stable lipid assembly comprising as a first active entity an apoptosis-affecting lipid which does not self-aggregate in a polar environment to form liposomes and a lipopolymer. The pharmaceutical composition further comprises, as the second active entity, a cytotoxic amphipathic weak base drug carried by the lipid assembly or by a different liposome. According to one embodiment, the apoptotic-affecting lipid is a pro-apoptotic lipid. A preferred pro-apoptotic lipid is ceramide, preferably C6-ceramide. The cytotoxic amphipathic weak base drug is preferably doxorubicin or a biologically active, anthracyline-based doxorubicin analog thereof.

The invention discloses ceramide-containing tea seed extract and a preparation method thereof. The preparation method comprises the following steps of: crushing raw materials, extracting by using water or low-carbon alcohol, and recycling an extraction solvent from the obtained extracting solution so as to obtain extract, wherein the raw materials are seeds of theaceae camellia plants, namely camellia oleifera abel, camellia or common camellia, or residues of the seeds of the plants subjected to oil component extraction; adding alkaline solution into the extract, and hydrolyzing at the temperature of between 10 and 80 DEG C for 0.5 to 20 hours; and separating the obtained hydrolyzate by using a macroporous resin column, performing chromatography through a silica gel column or a sephadex column, eluting by using 40 to 60 volume percent aqueous solution of methanol or ethanol, performing thin layer chromatography, collecting fractions, mixing the fractions, and drying to obtain the ceramide-containing tea seed extract. The raw materials are readily available and the method is environmentally-friendly; the preparation process is simple; the product quality is stable; the production cost is low; and the content of ceramide in the extract is high.

The invention discloses a cosmetic composition for repairing the corneous layer of skin. The cosmetic composition comprises an active ingredient, and a carrier component which can be contacted in cosmetology, wherein the active ingredient comprises the following components in percentage by mass: 30 to 60 percent of camellia oil, 20 to 50 percent of ceramide, 5 to 35 percent of cholesterol, 5 to 35 percent of higher aliphatic alcohol, 2 to 30 percent of lecithin, and 0.1 to 25 percent of vitamin and derivatives thereof. The absorptivity and the permeability of physiological lipids are improved by the cosmetic composition, and the cosmetic composition can well penetrate into clearances of cells and accelerates the recovery of a barrier function of the damaged corneous layer of the skin, so the state of the skin is improved. The cosmetic composition has a good market prospect.

Compounds, pharmaceuticals, cosmetic or dietary supplements for the treatment of overweight, obesity and / or type II diabetes in a mammal (e.g. human) comprising a compound with formula I or formula II for example ceramidase-inhibitor, such as (1S,2R)-D-ery-thro-2-(N-myristoylamino)-1-phenyl-1-propanol, alone or in combination with an anorexic lipid (or other appetite-inhibiting acylamides or oleoyl-estrone), and methods of treatment comprising administration of said compounds, pharmaceuticals, cosmetic or a dietary supplements. The compounds, pharmaceuticals, cosmetic or dietary supplements and methods of the invention may further be used in modifying the feeding behaviour, suppression of hunger, enhancement of satiety, reduction of energy intake, reduction of fat tissue mass / lean mass ratio in a mammal (e.g. human).

The present invention provides compositions and methods for human neural cell production. More particularly, the present invention provides cellular differentiation methods employing amphiphilic lipid compounds, preferably ceramide analogs of the β-hydroxyalkylamine type and optionally employing an essentially serum free MEDII conditioned medium for the generation of human neural cells from pluripotent human cells. The methods alternatively comprise modulating apoptosis by modifying the levels of PAR-4, with or without the presence of amphiphilic lipid compounds and optionally employing MEDII conditioned medium. The methods alternatively encompass modulating apoptosis by modulating the intracellular concentration of endogenous lipid second messengers, such as ceramide.

The invention provides a biomarker for diagnosing white matter lesion and application thereof. The biomarker is ceramide (d18: 0 / 24: 1 (15Z)) (Cer (d18: 0 / 24: 1 (15Z))). According to the present invention, the biomarker ceramide (d18: 0 / 24: 1 (15Z)) is combined with cholesterol-alpha-D-glucoside (Cholesteryl-alpha-D-glucoside), and is combined with 6Z, 9Z, 20-eicosatrienoic acid (6Z, 9Z, 20-Henecosatriene), ephedrine A (Cannflavanin A), cucurbitacine E (Cucurbitacine E) or cholesteryl ester 22: 6 (22: 6 Cholesteryl ester) so as to determine whether the white matter lesion exists or not; the biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.

The invention provides a biomarker for diagnosing white matter lesion and application thereof. The biomarker is cholesterol-alpha-D-glucoside. The biomarker cholesterol-alpha-D-glucoside is combined with 6Z,9Z,20-eicosatrienoic acid, ceramide (m18:1(4E) / 24:1(15Z)), ephedrine A, cucurbitacine E, cholesteryl ester 22:6 or ceramide (d18:0 / 24:1(15Z)) to judge whether white matter lesion exists or not. The biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.

A composition and process for treating a keratinous substrate involving contacting the keratinous substrate with a composition containing: a) at least one quaternary ammonium polymer; b) at least one fatty quaternary agent; c) at least one nonionic surfactant; and d) optionally, at least one ceramide, and wherein the composition is substantially anhydrous.

The invention discloses application of a product for detecting ceramide in preparation of a kit. The application of the kit is at least one of the following (a1)-(a3): (a1) screening or assisting in diagnosing heart failure patients; (a2) evaluating or assisting in evaluating the prognosis risk of heart failure patients; and (a3) evaluating or assisting in evaluating the adverse event risk of heart failure patients. Research results show that the ratio of plasma ceramide cer (d18: 1 / 16: 0) to cer (d18: 1 / 24: 0) is an important predictive factor for the occurrence of adverse events of heart failure in patients with heart failure at the final stage, and is independent of currently used lipid markers, which facilitates the identification of high risk patients requiring more positive therapeutic interventions.

The invention belongs to the field of infant skin care products, and particularly relates to a segmented fat-strengthening skin-care composition for barrier protection of infant skin. The skin-care composition comprises ceramide, phytosphingosine, cholesterol, D-panthenol, sodium hyaluronate, sunflower seed oil, evening primrose seed oil and the like. According to the invention, ceramide, phytosphingosine, cholesterol and D-panthenol are compounded according to a certain ratio, and the content ratio of the above components in the infant skin-care composition is adjusted according to the characteristics of the development and maturation of skins of infants in different age groups, so an accurately designed segmented fat-strengthening skin-care component formula can be obtained, and a synergistic barrier protection effect on infant skin is achieved.

The invention discloses a skincare product with a ceramide composition. The skincare product comprises the following components: caprylic / capric triglyceride, white oil, glycerinum, stearic acid, cetostearyl alcohol, polydimethyl siloxane, petroleum jelly, camellia-seed oil, cetearyl glucoside, glyceryl stearate, PEG-100 glyceryl stearate, an essence, EDTA (ethylene diamine tetraacetic acid) disodium, caprylhydroxamic acid, p-hydroxyacetophenone, polyacrylamide, C13-14 isoparaffin, polyoxyethylene 7 lauryl ether, ceramide compositions, carbopol, sodium hydroxide, allantoin, butanediol, plant extracts and the balance of purified water. The skincare product is applicable to various types of skin, activity of skin can be recovered, and metabolism can be promoted. By adjusting the ratio of ceramide, the balance of moisture of stratum corneum can be maintained, and skin barrier functions lost because of use of organic solvents or surfactants can be recovered.

The invention relates to a method for extracting ceramide-rich lipid by adopting a green supercritical extraction technology and taking cheap byproducts of agriculture and forestry raw materials, and the method has unlimited market potential and values of ecological and environment friendliness. During the operation of supercritical extraction equipment, temperature is controlled to 60 to 100 DEG C, pressure is controlled to 10 to 30 MPa, and time is controlled to 1 to 3 hours; during the operation, 10-20% methanol and ethanol as entrainers are added, and then extract liquid is obtained, and is rotated and evaporated to dryness to obtain the ceramide-rich active lipid; and after alkali treatment, ceramide is separated by high-efficiency liquid chromatography. The method disclosed by the invention belongs to a green technology, has the advantages of high extraction yield, simplified separation steps and low cost, and simultaneously can be used for obtaining ceramide lipid in different contents.

Among the various aspects of the present disclosure is the provision of a method of detecting ceramides as prognostic indicators. An aspect of the present disclosure provides for a prognostic indicator for risk of developing a cardiovascular-related disease, disorder, or condition and mortality risk.

The present disclosure relates to bi-phase micellar liquid products that include ceramides and other components that are beneficial to the skin. In particular, the products include: (a) a fatty phase comprising one or more fatty compounds and one or more silicones; and (b) an aqueous phase comprising one or more ceramides, one or more water-soluble solvents, one or more surfactants, and water. The products are particularly unique because the ceramides are solubilized in the aqueous phase of the products. In addition to being useful for cleansing the skin, the products support natural lipid barrier function of the skin and improve skin hydration.

Provided is a method for preparing a nanoemulsion, including mixing an oil phase part (A) containing a ceramide or derivative thereof, cholesterol, non-ionic surfactant, phospholipid and a polyol, a perfume part (B) containing a perfume ingredient, non-ionic surfactant and an alcohol, and an aqueous phase part (C) containing the other water-soluble active ingredients. When a nanoemulsion is obtained by the method, it is possible to reduce processing time and cost since a non-ionic surfactant is used without a high-pressure emulsification process, and the obtained nanoemulsion is more stable against a change in temperature than the other solubilized formulations.

The invention discloses a preparation method and product of a ceramide and fat-soluble active matter skin co-permeation carrier, and the ceramide and fat-soluble active matter skin co-permeation carrier comprises ceramide, fat-soluble active matter, phospholipid, cholesterol, fatty acid, phytosphingosine, liquid lipid, solid lipid, polyhydric alcohol and water. The carrier is positively charged; aternary permeation-promoting system can significantly improve the permeation amount of the ceramide in the cuticle of the skin, and the effects of the ceramide to enhance skin hydration and improve lipid fluidity of the cuticle are exerted, and thus, skin permeation of the fat-soluble active matter in the carrier is promoted, and the purpose of co-permeation is achieved.

The invention discloses astaxanthin essence and a preparation process thereof, which belongs to the field of cosmetic, the technical scheme of the astaxanthin essence is that the astaxanthin essence is prepared by the following raw materials in parts by weight, 88.13 to 91.09 parts of water, 3 to 5 parts of butanediol, 0.02 to 0.08 parts of a chelating agent, 0.1 to 0.3 part of hydroxyethyl cellulose, 0.02 to 0.06 part of sodium hyaluronate, 0.5 to 1.5 parts of beta-glucan, 0.8 to 1.6 parts of ceramide, 2.5 to 4.5 parts of leupeptin antibacterial liquid, 0.003 to 0.005 parts of astaxanthin, 0.39 to 0.41 part of an antioxidant inhibitor, paraffin oil, vitamin C, BHT and Na2SO3. The effect of prolonging the service life of the astaxanthin essence is achieved.

The invention discloses an essence composition for delaying skin aging and a preparation method thereof, and belongs to the technical field of cosmetics. Through the key points of the technology, theessence composition for delaying skin aging comprises the following components in parts by weight: 0.025 to 0.2 part of N-palmitoyl hydroxyproline cetyl ester, 0.2 to 1 part of p-hydroxyacetophenone,0.001 to 0.02 part of tocopherol, 0.01 to 0.05 part of astaxanthin, 0.01 to 0.1 part of a ginger root extract, 0.001 to 0.01 part of acetyl hexapeptide-8, 0.05 to 0.5 parts of hydrolyzed collagen, 0.1to 1.0 part of carnosine, 0.01 to 0.16 part of compound ceramide and 0.11 to 1.33 parts of a thickening agent, 5 to 31 parts of humectant, 0.13 to 1.2 parts of a skin conditioner, 0.93 to 8.5 parts of an emollient and 62 to 95 parts of water. The compound ceramide is selected from one or more of ceramide 3, ceramide 6II, ceramide 1 and ceramide 2. The preparation method is safe and convenient tooperate, the skin aging can be delayed, the collagen generation is promoted, the filling degree of the skin is improved, the moisture content of the stratum corneum is increased, and the essence composition has a good anti-aging effect.

A method of treating polycystic kidney disease in a subject comprises administering to the subject an effective amount of a compound represented by Structural Formula (1):or a pharmaceutically acceptable salt thereof.

The present disclosure relates to cosmetic compositions, typically in the form of an emulsion, comprising cholesterol, at least one ceramide, and oils. The compositions are particularly useful for supporting natural lipid barrier function of skin. Furthermore, the compositions treat skin dryness, skin damage, and the appearance of wrinkles, dark spots, and uneven skin texture. Also disclosed is a process for manufacturing the cosmetic compositions.